JP2011520918A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011520918A5 JP2011520918A5 JP2011509783A JP2011509783A JP2011520918A5 JP 2011520918 A5 JP2011520918 A5 JP 2011520918A5 JP 2011509783 A JP2011509783 A JP 2011509783A JP 2011509783 A JP2011509783 A JP 2011509783A JP 2011520918 A5 JP2011520918 A5 JP 2011520918A5
- Authority
- JP
- Japan
- Prior art keywords
- relaxin
- heart failure
- treatment
- subject
- pharmaceutically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003743 Relaxin Human genes 0.000 claims description 86
- 108090000103 Relaxin Proteins 0.000 claims description 86
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 33
- 206010013975 Dyspnoeas Diseases 0.000 claims description 28
- 208000000059 Dyspnea Diseases 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 16
- 230000002861 ventricular Effects 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 238000001990 intravenous administration Methods 0.000 claims description 12
- 238000001802 infusion Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 6
- 230000035488 systolic blood pressure Effects 0.000 claims description 6
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 239000002171 loop diuretic Substances 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 229940030600 antihypertensive agent Drugs 0.000 description 3
- 229940124549 vasodilator Drugs 0.000 description 3
- 239000003071 vasodilator agent Substances 0.000 description 3
- 206010037368 Pulmonary congestion Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000288140 Gruiformes Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000009378 Low Cardiac Output Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000011863 diuretic therapy Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000002642 intravenous therapy Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12788908P | 2008-05-16 | 2008-05-16 | |
| US61/127,889 | 2008-05-16 | ||
| US19054508P | 2008-08-28 | 2008-08-28 | |
| US61/190,545 | 2008-08-28 | ||
| US20124008P | 2008-12-08 | 2008-12-08 | |
| US61/201,240 | 2008-12-08 | ||
| US16433309P | 2009-03-27 | 2009-03-27 | |
| US61/164,333 | 2009-03-27 | ||
| PCT/US2009/044249 WO2009140659A2 (en) | 2008-05-16 | 2009-05-15 | Method of treating dyspnea associated with acute heart failure |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012200728A Division JP5638044B2 (ja) | 2008-05-16 | 2012-09-12 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011520918A JP2011520918A (ja) | 2011-07-21 |
| JP2011520918A5 true JP2011520918A5 (enExample) | 2012-11-01 |
| JP5651586B2 JP5651586B2 (ja) | 2015-01-14 |
Family
ID=40834101
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011509783A Expired - Fee Related JP5651586B2 (ja) | 2008-05-16 | 2009-05-15 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
| JP2012200728A Expired - Fee Related JP5638044B2 (ja) | 2008-05-16 | 2012-09-12 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
| JP2014165276A Expired - Fee Related JP5875646B2 (ja) | 2008-05-16 | 2014-08-14 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
| JP2015201153A Pending JP2016053040A (ja) | 2008-05-16 | 2015-10-09 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012200728A Expired - Fee Related JP5638044B2 (ja) | 2008-05-16 | 2012-09-12 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
| JP2014165276A Expired - Fee Related JP5875646B2 (ja) | 2008-05-16 | 2014-08-14 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
| JP2015201153A Pending JP2016053040A (ja) | 2008-05-16 | 2015-10-09 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US8053411B2 (enExample) |
| EP (2) | EP2288373B1 (enExample) |
| JP (4) | JP5651586B2 (enExample) |
| CN (3) | CN103212063B (enExample) |
| AR (1) | AR071810A1 (enExample) |
| AU (1) | AU2009246114B2 (enExample) |
| BR (1) | BRPI0913011A2 (enExample) |
| CA (1) | CA2724540C (enExample) |
| CR (1) | CR11749A (enExample) |
| CY (1) | CY1116925T1 (enExample) |
| DK (1) | DK2288373T3 (enExample) |
| EA (2) | EA022948B1 (enExample) |
| ES (1) | ES2546287T3 (enExample) |
| GB (2) | GB2459983B (enExample) |
| HK (1) | HK1202054A1 (enExample) |
| HR (1) | HRP20150845T1 (enExample) |
| HU (1) | HUE025483T2 (enExample) |
| IL (3) | IL208992A (enExample) |
| MA (1) | MA32389B1 (enExample) |
| MX (1) | MX2010012450A (enExample) |
| MY (2) | MY159803A (enExample) |
| NZ (3) | NZ701038A (enExample) |
| PL (1) | PL2288373T3 (enExample) |
| PT (1) | PT2288373E (enExample) |
| SG (2) | SG191587A1 (enExample) |
| SI (1) | SI2288373T1 (enExample) |
| TW (1) | TWI386202B (enExample) |
| UA (1) | UA99953C2 (enExample) |
| WO (1) | WO2009140659A2 (enExample) |
| ZA (1) | ZA201007449B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR071810A1 (es) | 2008-05-16 | 2010-07-14 | Corthera Inc | Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso. |
| WO2009140657A2 (en) * | 2008-05-16 | 2009-11-19 | Corthera, Inc. | Method of treating chronic heart failure |
| RU2564900C2 (ru) * | 2010-03-10 | 2015-10-10 | Дзе Юниверсити Оф Флорида Рисерч Фаундейшн, Инк. | Модулирование аквапоринов релаксином |
| US8501418B2 (en) | 2010-08-06 | 2013-08-06 | Pronata N.V. | Method of treating renal dysfunction based on perlecan as a biomarker |
| EP3572091B1 (en) | 2010-08-17 | 2023-12-13 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| CN103930440A (zh) * | 2011-07-01 | 2014-07-16 | 拜耳知识产权有限责任公司 | 松弛素融合多肽及其用途 |
| WO2013059879A1 (en) * | 2011-10-26 | 2013-05-02 | Howard Florey Institute Of Experimental Physiology And Medicine | Compositions and methods for the treatment of fibrosis and fibrotic diseases |
| KR102107482B1 (ko) * | 2012-02-14 | 2020-05-08 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 심혈관 질환 및 다른 증상에 대한 파라크린 유전자의 전신 전달 및 조절 발현 |
| EP2844345B1 (en) | 2012-05-04 | 2022-08-03 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Modulators of the relaxin receptor 1 |
| EP2925128B1 (en) | 2012-10-26 | 2018-04-11 | Chiesi Farmaceutici S.p.A. | Methods for controlling blood pressure and reducing dyspnea in heart failure |
| EP2981258B8 (en) * | 2013-04-05 | 2020-11-11 | scPharmaceuticals Inc. | Pharmaceutical formulations for subcutaneous administration of furosemide |
| US9707154B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| EA201691562A2 (ru) * | 2014-02-03 | 2017-01-30 | Новартис Аг | Фильтры для инфузионных наборов |
| EP2946788A1 (en) * | 2014-05-23 | 2015-11-25 | Immundiagnostik AG | Method and composition for treating heart failure with preserved ejection fraction |
| AU2015273097A1 (en) * | 2014-06-13 | 2016-11-17 | Novartis Ag | Use of serelaxin to reduce GDF-15 |
| EP4011919A3 (en) | 2015-12-09 | 2022-10-12 | The Scripps Research Institute | Relaxin immunoglobulin fusion proteins and methods of use |
| EP3413783B1 (en) | 2016-02-12 | 2025-01-22 | Cardiac Pacemakers, Inc. | Systems and methods for patient monitoring |
| WO2018148419A1 (en) | 2017-02-08 | 2018-08-16 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
| US11832970B2 (en) | 2017-07-26 | 2023-12-05 | Cardiac Pacemakers, Inc. | Worsening heart failure stratification |
| CN107335051A (zh) * | 2017-08-18 | 2017-11-10 | 温州医科大学附属第医院 | 一种保护慢性心衰肾功能的药物组合物 |
| WO2020120482A1 (en) | 2018-12-10 | 2020-06-18 | Sq Innovation Ag | Pharmaceutical compositions of furosemide and uses thereof |
| US12397005B2 (en) | 2019-01-04 | 2025-08-26 | Sq Innovation Ag | Pharmaceutical compositions of torsemide and uses thereof |
| CN113271923B (zh) | 2019-01-04 | 2025-05-13 | Sq创新股份公司 | 呋塞米的药物组合物及其用途 |
| PH12021551811A1 (en) | 2019-01-31 | 2022-03-21 | Scpharmaceuticals Inc | Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same |
| CN119947743A (zh) | 2022-08-31 | 2025-05-06 | 雷拉科斯拉制药有限责任公司 | 免疫抑制药物及治疗方法 |
| WO2025056188A1 (en) | 2023-09-15 | 2025-03-20 | Relaxera Pharmazeutische Gmbh & Co. Kg | Relaxin medication |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023321A (en) | 1982-12-13 | 1991-06-11 | Howard Florey Institute Of Experimental Physiology & Medicine | Molecular cloning and characterization of a further gene sequence coding for human relaxin |
| US5166191A (en) * | 1991-08-19 | 1992-11-24 | Genentech, Inc. | Use of relaxin in cardiovascular therapy |
| US5478807A (en) * | 1991-08-19 | 1995-12-26 | Genentech, Inc. | Use of relaxin in the treatment of bradycardia |
| EP0707650B1 (en) | 1993-06-21 | 2003-05-21 | Genentech, Inc. | Process for producing human relaxin |
| EP0675732B1 (en) | 1993-07-27 | 2006-06-28 | Mario Bigazzi | Use of relaxin in the manufacture of therapeutic agents |
| US5760069A (en) | 1995-02-08 | 1998-06-02 | Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 | Method of treatment for decreasing mortality resulting from congestive heart failure |
| US5811395A (en) * | 1995-06-07 | 1998-09-22 | Medical University Of South Carolina | Relaxin analogs and derivatives methods and uses thereof |
| CA2229479C (en) | 1995-08-15 | 2010-03-30 | Connective Therapeutics, Inc. | Method of promoting angiogenesis |
| DE60128540T2 (de) * | 2000-02-09 | 2008-01-31 | Bas Medical, Inc., San Mateo | Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen |
| DE10155843A1 (de) | 2000-11-16 | 2003-01-30 | Immundiagnostik Ag | Verfahren zur Prognose und Diagnose von Herzinsuffizienz |
| US20050113286A1 (en) * | 2002-03-18 | 2005-05-26 | Schreiner George F. | Methods for treating congestive heart failure |
| US7878978B2 (en) * | 2004-03-18 | 2011-02-01 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Use of relaxin to increase arterial compliance |
| EP1729817B1 (en) * | 2004-03-30 | 2014-03-05 | Industry-Academic Cooperation Foundation | Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin |
| US20060264367A1 (en) | 2005-05-21 | 2006-11-23 | Howard Florey Institute | Prevention of fibrosis following cardiac injury |
| WO2007008907A2 (en) * | 2005-07-11 | 2007-01-18 | Abbott Laboratories | Methods for determining how to treat congestive heart failure |
| JP5355561B2 (ja) | 2007-07-12 | 2013-11-27 | コンピュゲン エルティーディー． | 生物活性ペプチドおよびその使用方法 |
| WO2009140657A2 (en) | 2008-05-16 | 2009-11-19 | Corthera, Inc. | Method of treating chronic heart failure |
| AR071810A1 (es) * | 2008-05-16 | 2010-07-14 | Corthera Inc | Metodo de tratamiento de la disnea asociada con la insuficiencia cardiaca aguda. relaxina h2. uso. |
-
2009
- 2009-05-15 AR ARP090101762A patent/AR071810A1/es unknown
- 2009-05-15 EA EA201001771A patent/EA022948B1/ru not_active IP Right Cessation
- 2009-05-15 GB GB0908432A patent/GB2459983B/en not_active Expired - Fee Related
- 2009-05-15 UA UAA201012879A patent/UA99953C2/uk unknown
- 2009-05-15 EA EA201500552A patent/EA201500552A1/ru unknown
- 2009-05-15 BR BRPI0913011A patent/BRPI0913011A2/pt not_active IP Right Cessation
- 2009-05-15 SI SI200931246T patent/SI2288373T1/sl unknown
- 2009-05-15 DK DK09747740.0T patent/DK2288373T3/en active
- 2009-05-15 JP JP2011509783A patent/JP5651586B2/ja not_active Expired - Fee Related
- 2009-05-15 WO PCT/US2009/044249 patent/WO2009140659A2/en not_active Ceased
- 2009-05-15 EP EP09747740.0A patent/EP2288373B1/en active Active
- 2009-05-15 GB GB0918132A patent/GB2462221B/en not_active Expired - Fee Related
- 2009-05-15 PL PL09747740T patent/PL2288373T3/pl unknown
- 2009-05-15 CA CA2724540A patent/CA2724540C/en not_active Expired - Fee Related
- 2009-05-15 TW TW098116328A patent/TWI386202B/zh not_active IP Right Cessation
- 2009-05-15 MX MX2010012450A patent/MX2010012450A/es active IP Right Grant
- 2009-05-15 CN CN201310127326.6A patent/CN103212063B/zh not_active Expired - Fee Related
- 2009-05-15 CN CN2009801177504A patent/CN102036679A/zh active Pending
- 2009-05-15 AU AU2009246114A patent/AU2009246114B2/en not_active Ceased
- 2009-05-15 HR HRP20150845TT patent/HRP20150845T1/hr unknown
- 2009-05-15 CN CN201610565105.0A patent/CN106177914A/zh active Pending
- 2009-05-15 MY MYPI2010005049A patent/MY159803A/en unknown
- 2009-05-15 SG SG2013038260A patent/SG191587A1/en unknown
- 2009-05-15 US US12/467,214 patent/US8053411B2/en not_active Expired - Fee Related
- 2009-05-15 ES ES09747740.0T patent/ES2546287T3/es active Active
- 2009-05-15 EP EP14167842.5A patent/EP2829280A1/en not_active Withdrawn
- 2009-05-15 NZ NZ701038A patent/NZ701038A/en not_active IP Right Cessation
- 2009-05-15 US US12/992,356 patent/US8415301B2/en not_active Expired - Fee Related
- 2009-05-15 PT PT97477400T patent/PT2288373E/pt unknown
- 2009-05-15 NZ NZ589009A patent/NZ589009A/en not_active IP Right Cessation
- 2009-05-15 NZ NZ598709A patent/NZ598709A/xx not_active IP Right Cessation
- 2009-05-15 SG SG10201609580YA patent/SG10201609580YA/en unknown
- 2009-05-15 HU HUE09747740A patent/HUE025483T2/en unknown
-
2010
- 2010-10-19 ZA ZA2010/07449A patent/ZA201007449B/en unknown
- 2010-10-22 CR CR11749A patent/CR11749A/es unknown
- 2010-10-28 IL IL208992A patent/IL208992A/en not_active IP Right Cessation
- 2010-12-10 MA MA33418A patent/MA32389B1/fr unknown
-
2011
- 2011-05-30 HK HK15102533.3A patent/HK1202054A1/en unknown
- 2011-09-23 US US13/242,012 patent/US8372809B2/en not_active Expired - Fee Related
-
2012
- 2012-09-12 JP JP2012200728A patent/JP5638044B2/ja not_active Expired - Fee Related
-
2013
- 2013-01-04 US US13/734,301 patent/US9066916B2/en not_active Expired - Fee Related
- 2013-03-05 US US13/784,963 patent/US9205132B2/en not_active Expired - Fee Related
- 2013-09-02 IL IL228244A patent/IL228244A/en not_active IP Right Cessation
- 2013-11-28 MY MYPI2013004312A patent/MY158327A/en unknown
-
2014
- 2014-08-14 JP JP2014165276A patent/JP5875646B2/ja not_active Expired - Fee Related
-
2015
- 2015-05-28 US US14/723,701 patent/US9579363B2/en not_active Expired - Fee Related
- 2015-09-18 CY CY20151100824T patent/CY1116925T1/el unknown
- 2015-10-09 JP JP2015201153A patent/JP2016053040A/ja active Pending
-
2016
- 2016-08-18 IL IL247351A patent/IL247351A0/en unknown
-
2017
- 2017-01-23 US US15/412,447 patent/US20170151311A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011520918A5 (enExample) | ||
| Miller et al. | Afterload reduction therapy with nitroprusside in severe aortic regurgitation: improved cardiac performance and reduced regurgitant volume | |
| Taguchi et al. | Effects of enhanced external counterpulsation on hemodynamics and its mechanism relation to neurohumoral factors | |
| Weir | Diltiazem: ten years of clinical experience in the treatment of hypertension | |
| Figueras et al. | Prognostic implications of early spontaneous angina after acute transmural myocardial infarction | |
| Burckhartt et al. | Coronary artery slow flow associated with angina pectoris and hypotension: a case report | |
| McClean et al. | Effects of omapatrilat on systemic arterial function in patients with chronic heart failure | |
| Yeh et al. | Sodium nitroprusside as a coronary vasodilator in man: I. Effect of intracoronary sodium nitroprusside on coronary arteries, angina pectoris, and coronary blood flow | |
| Cantelli et al. | Comparison of acute haemodynamic effects of nifedipine and isosorbide dinitrate in patients with heart failure following acute myocardial infarction | |
| CN119156218A (zh) | 用于治疗心源性休克前期和心源性休克的含有istaroxime的静脉内制剂 | |
| WO2013030564A1 (en) | Vascular treatments | |
| Bauer et al. | Rapid reduction of severe hypertension with minoxidil | |
| Aronow | Ten key points from the American College of Cardiology Foundation/American Heart Association 2011 expert consensus document on hypertension in the elderly | |
| Chandraratna et al. | Use of Nitroglycerin Ointment in Congestive Heart Failure: Results of Acute and Chronic Therapy | |
| Johnson et al. | Treatment of shock in myocardial infarction | |
| Mehta et al. | Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure. | |
| Koliopoulos et al. | Pinacidil, a new vasodilator, in the treatment of patients with moderate to severe hypertension | |
| Laakshmi | Non-Pharmacological Therapies for Treatment of Heart Failure-An Update | |
| Houde et al. | Indapamide for out-patient treatment of hypertension: modifications in serum catecholamine levels | |
| Ikram et al. | Haemodynamic effects of dobutamine in patients with congestive heart failure receiving captopril. | |
| Kramer et al. | Controlled trial of captopril for heart failure: Effects on hemodynamics, scintigraphy and exercise tolerance | |
| Shin et al. | REAL WORLD EFFICACY OF NEBIVOLOL IN COMBINATION WITH RENIN ANGIOTENSIN SYSTEM BLOCKADE AND/OR CALCIUM ANTAGONIST, A SUB-STUDY OF PROSPECTIVE, MULTICENTER OBSERVATIONAL STUDY | |
| Hill et al. | Orthostatic Hypotension following Right Ventricular Myocardial Infarction Corrected with Mineralocorticoid Therapy | |
| Cody et al. | Captopril pharmacokinetics in chronic heart failure: Correlation with acute hemodynamic and hormonal response | |
| Sharp et al. | Nesiritide for treatment of heart failure due to right ventricular dysfunction |